Literature DB >> 19013938

Targeting reward-relevant nicotinic receptors in the discovery of novel pharmacotherapeutic agents to treat tobacco dependence.

Linda P Dwoskin1, Marharyta Pivavarchyk, B Matthew Joyce, Nichole M Neugebauer, Guangrong Zheng, Zhenfa Zhang, Michael T Bardo, Peter A Crooks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19013938      PMCID： PMC3090004          DOI： 10.1007/978-0-387-78748-0_4

Source DB:  PubMed          Journal:  Nebr Symp Motiv        ISSN： 0146-7875


× No keyword cloud information.
  142 in total

1.  Decrease in alpha3*/alpha6* nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage.

Authors:  Sarah E McCallum; Neeraja Parameswaran; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2005-06-02       Impact factor: 4.436

2.  Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats.

Authors:  A Imperato; A Mulas; G Di Chiara
Journal:  Eur J Pharmacol       Date:  1986-12-16       Impact factor: 4.432

Review 3.  A psychomotor stimulant theory of addiction.

Authors:  R A Wise; M A Bozarth
Journal:  Psychol Rev       Date:  1987-10       Impact factor: 8.934

4.  Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.

Authors:  P B Clarke; A Pert
Journal:  Brain Res       Date:  1985-12-02       Impact factor: 3.252

5.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

6.  Nicotine maintains robust self-administration in rats on a limited-access schedule.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Expression of nigrostriatal alpha 6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by beta 3 subunit gene deletion.

Authors:  Cecilia Gotti; Milena Moretti; Francesco Clementi; Loredana Riganti; J Michael McIntosh; Allan C Collins; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

8.  Beta 3: a new member of nicotinic acetylcholine receptor gene family is expressed in brain.

Authors:  E S Deneris; J Boulter; L W Swanson; J Patrick; S Heinemann
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

9.  Effects of dopaminergic nucleus accumbens lesions on the acquisition of schedule induced self injection of nicotine in the rat.

Authors:  G Singer; M Wallace; R Hall
Journal:  Pharmacol Biochem Behav       Date:  1982-09       Impact factor: 3.533

10.  Distribution of alpha 2, alpha 3, alpha 4, and beta 2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat.

Authors:  E Wada; K Wada; J Boulter; E Deneris; S Heinemann; J Patrick; L W Swanson
Journal:  J Comp Neurol       Date:  1989-06-08       Impact factor: 3.215
View more
  8 in total

1.  Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [³H]dopamine and [³H]norepinephrine release.

Authors:  Vidya Narayanaswami; Sucharita S Somkuwar; David B Horton; Lisa A Cassis; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2013-07-04       Impact factor: 5.858

Review 2.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

Review 3.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

4.  Bis-azaaromatic quaternary ammonium salts as ligands for the blood-brain barrier choline transporter.

Authors:  Guangrong Zheng; Zhenfa Zhang; Paul R Lockman; Werner J Geldenhuys; David D Allen; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-24       Impact factor: 2.823

Review 5.  Targeting nicotinic receptor antagonists as novel pharmacotherapies for tobacco dependence and relapse.

Authors:  Linda P Dwoskin; Michael T Bardo
Journal:  Neuropsychopharmacology       Date:  2009-01       Impact factor: 7.853

6.  Novel bis-2,2,6,6-tetramethylpiperidine (bis-TMP) and bis-mecamylamine antagonists at neuronal nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Zhenfa Zhang; Marharyta Pivavarchyk; Karunai Leela Subramanian; A Gabriela Deaciuc; Linda P Dwoskin; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-01-04       Impact factor: 2.823

7.  The motivational impact of nicotine and its role in tobacco use: final comments and priorities.

Authors:  Michael T Bardo; Paul Schnur
Journal:  Nebr Symp Motiv       Date:  2009

8.  Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.

Authors:  Dean T Acheson; Elizabeth W Twamley; Jared W Young
Journal:  Front Neurosci       Date:  2013-06-18       Impact factor: 4.677
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.